Inclusion Criteria:

- Confirmed hepatocellular cancer (HCC) by pathology or by NCCN imaging guidelines

- All HCC stages are allowed. May be a liver transplant candidate.

- At least one tumor (index tumor) accurately measured as 3.5-7cm in diameter (long and
short axis diameter to be recorded, but only one needs to meet this criteria) on
baseline imaging.

- No prior therapy for the index tumor

- No prior systemic treatment for HCC within 4 weeks and no prior anti-VEGF therapy
within 8 weeks of study entry.

- Life expectancy > 8 weeks.

- ECOG >=0 or 1

- RFA clinically indicated for index tumor.

- Acceptable overall RFA and anesthesia risk.

- Adequate bone marrow, liver and renal function: Hemoglobin >9.0 g/dl; Absolute
neutrophil count (ANC)>1,500/mm3; Platelet count correctable to >50,000/mm3;
compensated liver function (Child-Turcotte-Pugh A, B7 or B8); Creatinine <1.5 times
ULN; INR correctable to <1.5.

- Ability to take oral medication and no evidence of impaired absorption.

Exclusion Criteria

- Urgent treatment of the index tumor anticipated.

- Participants who have not recovered from adverse events due to agents administered
more than 4 weeks earlier. Participants currently receiving any other study agents.

- Known brain metastases

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to sorafenib.

- Participants receiving medications or substances that are inducers of CYP3A4
(rifampicin, St. John's wort, phenytoin, carbamazepine, phenobarbital and
dexamethasone) or that are metabolized/eliminated by predominantly UGT1A1 pathway or
by CYP2B6 and CYP2C8.

- Decompensated liver disease

- Uncontrolled hypertension

- Thrombolic or embolic events within the past 6 months.

- Hemorrhage/bleeding event within 4 weeks

- Serious non-healing wound, ulcer, or bone fracture.

- Evidence of severe or uncorrectable bleeding diathesis or coagulopathy

- Major surgery, open biopsy or significant traumatic injury within 4 weeks of study
entry.

- Contraindication to or inability to undergo the RFA procedure,

- Contraindication to or inability to undergo imaging with MRI

- Uncontrolled intercurrent illness

- Individuals with a history of a different malignancy unless disease-free for at least
5 years and are deemed by the Investigator to be at low risk for recurrence.
Individuals with the following cancers are eligible if diagnosed and treated within
the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma
of the skin.

- HIV-positive individuals on combination antiretroviral therapy

For additional inclusion/exclusion criteria details contact Study Site.